These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24135952)

  • 1. Viro-immunological response and emergence of resistance in HIV-infected women receiving combination antiretroviral regimens for the prevention of mother-to-child transmission in Malawi.
    Palombi L; Galluzzo CM; Pirillo MF; Liotta G; Andreotti M; Jere H; Sagno JB; Luhanga R; Mancinelli S; Ceffa S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2014 Mar; 69(3):749-52. PubMed ID: 24135952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    Palombi L; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Luhanga R; Mancinelli S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2015 Oct; 70(10):2881-4. PubMed ID: 26111981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
    Mancinelli S; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Amici R; Pirillo MF; Scarcella P; Marazzi MC; Vella S; Palombi L; Giuliano M
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):737-42. PubMed ID: 27067142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High rates of baseline antiretroviral resistance among HIV-infected pregnant women in an HIV referral centre in Rio de Janeiro, Brazil.
    de Lourdes Teixeira M; Nafea S; Yeganeh N; Santos E; Gouvea MI; Joao E; Ceci L; Bressan C; Cruz ML; Sidi LC; Nielsen-Saines K
    Int J STD AIDS; 2015 Nov; 26(13):922-8. PubMed ID: 25504831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis.
    Duran AS; Losso MH; Salomón H; Harris DR; Pampuro S; Soto-Ramirez LE; Duarte G; de Souza RS; Read JS;
    AIDS; 2007 Jan; 21(2):199-205. PubMed ID: 17197811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance.
    Gingelmaier A; Eberle J; Kost BP; Bogner JR; Hofmann J; Weissenbacher T; Kästner R; Friese K; Weizsaecker K
    Clin Infect Dis; 2010 Mar; 50(6):890-4. PubMed ID: 20166821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
    Han J; Wang L; Jiang Y; Zhang Q; Fang L; Yao J; Wang Q
    Int J STD AIDS; 2009 Apr; 20(4):249-54. PubMed ID: 19304969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety.
    Palombi L; Pirillo MF; Andreotti M; Liotta G; Erba F; Sagno JB; Maulidi M; Ceffa S; Jere H; Marchei E; Pichini S; Galluzzo CM; Marazzi MC; Vella S; Giuliano M
    Antivir Ther; 2012; 17(8):1511-9. PubMed ID: 22910456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of human immunodeficiency virus-infected pregnant women at Latin American and Caribbean sites.
    Read JS; Cahn P; Losso M; Pinto J; Joao E; Duarte G; Cardoso E; Freimanis-Hance L; Stoszek SK;
    Obstet Gynecol; 2007 Jun; 109(6):1358-67. PubMed ID: 17540808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of HIV-1 drug-resistant variants in women following antiretroviral prophylaxis for the prevention of mother to child transmission.
    Mani M; Ramalingam VV; Lionel J; Christina SA; Sachithanandham J; Peedicayil A; Kannangai R
    Indian J Med Microbiol; 2015; 33(2):225-30. PubMed ID: 25865972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
    Bassetti D; Cargnel A
    Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers.
    Palacios R; Senise J; Vaz M; Diaz R; Castelo A
    HIV Med; 2009 Mar; 10(3):157-62. PubMed ID: 19245537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon.
    Meresse M; March L; Kouanfack C; Bonono RC; Boyer S; Laborde-Balen G; Aghokeng A; Suzan-Monti M; Delaporte E; Spire B; Carrieri MP; Laurent C;
    HIV Med; 2014 Sep; 15(8):478-87. PubMed ID: 24589279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retention, transfer out and loss to follow-up two years after delivery in a cohort of HIV+ pregnant women in Malawi.
    Giuliano M; Liotta G; Andreotti M; Mancinelli S; Buonomo E; Scarcella P; Amici R; Jere H; Sagno JB; Di Gregorio M; Marazzi MC; Vella S; Palombi L
    Int J STD AIDS; 2016 May; 27(6):462-8. PubMed ID: 25953961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virologic and immunologic failure, drug resistance and mortality during the first 24 months postpartum among HIV-infected women initiated on antiretroviral therapy for life in the Mitra plus Study, Dar es Salaam, Tanzania.
    Ngarina M; Kilewo C; Karlsson K; Aboud S; Karlsson A; Marrone G; Leyna G; Ekström AM; Biberfeld G
    BMC Infect Dis; 2015 Apr; 15():175. PubMed ID: 25886277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.